Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni
Phase of Trial: Phase II/III
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Rifaximin (Primary)
- Indications Campylobacter infections
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 06 Mar 2017 Status changed from active, no longer recruiting to completed.
- 30 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016.